INTRODUCTION {#s1}
============

Diabetes mellitus (DM) is a prevalent disease associated with considerable global health burden \[[@R1]\]. The number of patients with DM has significantly increased in the past few decades globally, especially in China \[[@R2], [@R3]\]. As DM is considered a risk factor for several types of cancer \[[@R4], [@R5]\], anti-diabetic medications (ADMs) have the potential to modify the risk of cancer \[[@R6], [@R7]\]. Metformin, an ADM, has been shown to exert antineoplastic effects through both insulin-dependent and insulin-independent mechanisms \[[@R8], [@R9]\]. However, data from various studies analyzing the anticancer effects of other types of ADMs, such as insulin, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors (AGIs), dipeptidyl peptidase-4 inhibitors, glinides, glucagon-like peptide-1 (GLP-1) agonists, and sodium glucose cotransporter type 2 inhibitors, are not consistent \[[@R7], [@R10]--[@R14]\]. AGIs such as acarbose, voglibose, and miglitol are commonly used oral hypoglycemic agents in China and other eastern Asian countries. The association between AGI and risk of cancer has been inconsistently reported.

A meta-analysis of 13 studies (6 case-control studies, 2 cohort studies, and 5 randomized controlled trials \[RCTs\]) published in 2015 concluded that AGI was associated with a significantly higher risk (10%) of cancer \[[@R7]\]. The meta-analysis noted a significant risk in the case-control studies, but not in the cohort studies or RCTs, compared with risk in the control population \[[@R7]\]. However, the meta-analysis had several limitations such as a mixture of studies with observational studies and RCTs; a mixture of studies with different tumor types; small case numbers in most studies; and lack of differentiation between cases of type 1 and type 2 diabetes. Studies published after this meta-analysis also yielded inconsistent results. Most recently, a cohort study of DM patients in Taiwan showed that acarbose use reduced the risk of incident colorectal cancer in patients with diabetes in a dose-dependent manner \[[@R15]\], but a cohort study performed in Italy did not find any association between AGI use and cancer risk \[[@R16]\].

Our objective was to conduct a systematic review and meta-analysis of observational studies and RCTs to investigate the effect of AGI use on cancer risk in patients with DM.

RESULTS {#s2}
=======

A total of 1399 unique studies were identified using the search strategy, of which 25 studies involving 1,285,433 patients with DM fulfilled the inclusion criteria and were pooled in the meta-analysis (14 cohort, 7 case-control, and 4 RCTs) \[[@R15]--[@R39]\].

Study characteristics {#s2_1}
---------------------

The study characteristics are shown in Table [1](#T1){ref-type="table"}. The earliest study period began in 1989 and the latest period ended in 2015. Fifteen of these studies were population-based studies, and the remaining 10 were hospital-based studies. Nineteen studies were from Asia and 5 studies were from Europe. One RCT was multicenter trial and included mixed populations (from China, Romania, and Spain). A majority of the included studies (22 studies) demonstrated cancer risk in patients with type 2 DM, and the remainders did not report the subtype of DM. Two studies assessed the modification of cancer risk with duration and dose of exposure to AGI \[[@R15], [@R34]\].

###### Characteristics of included studies assessing the risk of cancer in patients with DM on AGI

  Study                     Design   Location / setting          Time period; mean F/U (years)   Sample size (AGI/total)   Type of cancer                                           Type of DM   Mean duration of DM (years)   Mean age   Type of AGI   Exposure ascertainment                  Outcome ascertainment   Potential confounders
  ------------------------- -------- --------------------------- ------------------------------- ------------------------- -------------------------------------------------------- ------------ ----------------------------- ---------- ------------- --------------------------------------- ----------------------- -----------------------
  Nakamura, T\[[@R17]\]     RCT      Japan; HB                   NR; 1                           15/45                     NR                                                       2            16.8                          55.5       voglibose     RCT                                     Adverse event review    NR
  Pan, C\[[@R18]\]          RCT      China, Romania, Spain; HB   NR; 0.5                         220/661                   NR                                                       2            1.3                           51.9       Acarbose      RCT                                     Adverse event review    NR
  Kawaguchi, T\[[@R19]\]    C-C      Japan; HB                   2004.1-2008.12; NR              40/241                    Liver                                                    2            NR                            68.8       NR            HDMS                                    Medical record review   NR
  Yang, X\[[@R20]\]         Cohort   Hong Kong; HB               1996.12.1-2005.1.9; 4.9         829/6103                  NR                                                       2            6                             57         Acarbose      Medical record review                   ICD-9                   NR
  Bosco, J. L\[[@R21]\]     C-C      Denmark; PB                 1989-2008; NR                   204/4323                  Breast                                                   2            NR                            NR         NR            Prescription databases                  ICD-8 or ICD-10         NR
  Monami, M\[[@R22]\]       C-C      Italy; HB                   1998-2007, 6.3                  8/482                     NR                                                       2            8.4                           68.9       Acarbose      Medical record review                   ICD-9                   NR
  Tseng, C. H.\[[@R23]\]    Cohort   Taiwan; PB                  2003.1-2005.12; 3               NR/115731                 Bladder                                                  2            NR                            NR         Acarbose      NHI database                            ICD-9                   1, 2, 3, 7
  Tseng, C. H.\[[@R24]\]    Cohort   Taiwan; PB                  2003.1-2005.12; 3               NR/52131                  Prostate                                                 2            NR                            NR         Acarbose      NHI database                            ICD-9                   1, 2, 3, 7
  Chang, C. H.\[[@R25]\]    C-C      Taiwan; PB                  2000.12.31-2007.12.31; 7.9      3207/40969                Colon, Liver                                             2            New-onset                     NR         NR            Pharmacy prescription database          ICD-9                   NR
  Kawamori, R.\[[@R26]\]    RCT      Japan; HB                   2008-2010; 0.5                  162/561                   NR                                                       2            NR                            58.5       voglibose     RCT                                     Adverse event review    NR
  Lai, S. W.\[[@R28]\]      Cohort   Taiwan; PB                  2000-2008; 9                    4638/19624                Lung                                                     2            New-onset                     56.4       NR            NHI database                            ICD-9                   1, 2, 3
  Lai, S. W.\[[@R27]\]      Cohort   Taiwan; PB                  2000-2008; 9                    4449/19349                Liver                                                    2            New-onset                     56.4       NR            NHI database                            ICD-9                   1, 2, 3
  Liao, K. F.\[[@R29]\]     Cohort   Taiwan; PB                  1998--2007; NR                  12301/49803               Pancreas                                                 2            New-onset                     55.9       NR            NHI database                            ICD-9                   NR
  Tseng, C. H.\[[@R30]\]    Cohort   Taiwan; PB                  1996-2005; NR                   NR/115928                 Thyroid                                                  2            NR                            NR         NR            NHI database                            ICD-9                   1, 2, 3, 6, 7
  Chen, Y. L.\[[@R31]\]     Cohort   Taiwan; PB                  2000-2008; 5.5                  4472/19625                Gastric                                                  NR           New-onset                     56         Acarbose      NHI database                            ICD-9                   1, 2
  Chiu, C. C.\[[@R32]\]     Cohort   Taiwan; PB                  2000-2007; 7                    2918/39515                Colon, Esophagus, Gastric, Rectum, Pancreas, Liver       NR           New-onset                     58.52      NR            NHI database                            ICD-9                   1, 2, 3
  Origasa H,\[[@R33]\]      C-C      Japan; HB                   2005-2011; NR                   26/95                     Bladder                                                  2            NR                            69         NR            Medical record review                   Medical record review   1, 6
  Simo, R.\[[@R34]\]        C-C      Spain; HB                   2008-2010; NR                   115/2438                  NR                                                       2            6.4                           72.0       NR            Pharmacy prescription database          ICD-10                  1, 4, 5, 6, 8
  Chen, Y. C.\[[@R35]\]     Cohort   Taiwan; PB                  1998-2007; 2.5                  150/7325                  NR                                                       2            New-onset                     62.6       Acarbose      NHI database                            ICD-9                   1, 2, 3, 7
  Lin, C. M\[[@R36]\]       Cohort   Taiwan; PB                  2005--2010; NR                  NR /34823                 Lung, Liver, Colorectal, Breast, Oral cavity, Pancreas   2            New-onset                     54.26      NR            NHI database                            ICD-9                   1, 2, 3, 6
  Son, J. W.\[[@R37]\]      RCT      Korea; HB                   2008.2-2009.1; 0.3              81/156                    Gastric                                                  2            12.2                          56.1       voglibose     RCT                                     Adverse event review    NR
  Tseng, Y. H.\[[@R15]\]    Cohort   Taiwan; PB                  1998-2010; 3.4                  199296/398592             Colorectal                                               NR           New-onset                     54.1       Acarbose      NHI database                            ICD-9                   1, 2, 3, 6, 7
  Valent, F.\[[@R16]\]      Cohort   Italy; PB                   2002-2014; NR                   NR/109255                 Esophagus, Gastric, Colon, Rectum, Liver, Pancreas       2            NR                            NR         NR            Pharmaceutical prescription database,   ICD-9                   1, 2, 6
  Dabrowski, M.\[[@R38]\]   C-C      Poland; HB                  1998--2015; NR                  32/406                    NR                                                       2            10.7                          67.1       Acarbose      Medical record review                   Medical record review   3, 4, 6, 7, 8
  Tseng, C. H\[[@R39]\]     Cohort   Taiwan; PB                  1998-2009, NR                   47734/247252              Kidney                                                   2            New-onset                     NR         Acarbose      NHI database                            ICD-9                   NR

RCT, randomized controlled trial; C-C, case-control; PB, population based; HB, hospital based; DM, diabetes mellitus; F/U, follow-up; ICD-8/9/10, International Classification of Diseases, Eighth/Ninth/Tenth Revision; NR, not reported; NHI, National Health Insurance in Taiwan; HDMS, HCV-related diabetes mellitus study in Japan.

Potential confounders: 1 - age; 2 - sex; 3 - comorbidities; 4 - smoking; 5 - alcohol; 6 - diabetes status, including DM duration, DM control, other ADM use; 7 - social status, including living region, occupation, and income; 8 - BMI.

Quality of included studies {#s2_2}
---------------------------

The median Newcastle-Ottawa quality score for the observational studies was 7 (range 5-8). Table [2](#T2){ref-type="table"} depicts the methodological quality of all observational studies. The quality of the RCTs was moderate ([Figure S1](#SD1){ref-type="supplementary-material"}). The overall methodological quality of this body of evidence was moderate to high.

###### Assessment of quality of included studies using Newcastle-Ottawa Scale

  Cohort study                                                                                                                                                                                                                                                                                                                                                                     
  ------------------------- -------------------------------------- ------------------------------------- --------------------------- ---------------------------- ---------------------------------------------------------------------------- ------------------------------- --------------------------------------------------------- ----------------------- ----------------- ------------------
  Yang, X\[[@R20]\]         \*                                     \*                                    \*                          \*                           \*                                                                           \*                              \*                                                        \-                      7                 Low
  Tseng, C. H.\[[@R23]\]    \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                              \-                                                        \*                      8                 Low
  Tseng, C. H.\[[@R24]\]    \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                              \-                                                        \*                      8                 Low
  Lai, S. W.\[[@R28]\]      \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                              \*                                                        \-                      8                 Low
  Lai, S. W.\[[@R27]\]      \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                              \*                                                        \-                      8                 Low
  Liao, K. F.\[[@R29]\]     \*                                     \*                                    \*                          \*                           \*                                                                           \*                              \*                                                        \-                      7                 Low
  Tseng, C. H.\[[@R30]\]    \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                              \-                                                        \-                      7                 Low
  Chen, Y. L.\[[@R31]\]     \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                                                                                        \-                      8                 Low
  Chiu, C. C.\[[@R32]\]     \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                              \*                                                        \-                      8                 Low
  Chen, Y. C.\[[@R35]\]     \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                              \-                                                        \*                      8                 Low
  Lin, C. M\[[@R36]\]       \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                              \-                                                        \-                      7                 Low
  Tseng, Y. H.\[[@R15]\]    \*                                     \*                                    \*                          \*                           \*\*                                                                         \*                              \-                                                        \-                      7                 Low
  Valent, F.\[[@R16]\]      \*                                     \*                                    \*                          \*                           \*                                                                           \*                              \-                                                        \-                      6                 Moderate
  Tseng, C. H\[[@R39]\]     \*                                     \*                                    \*                          \*                           \-                                                                           \*                              \-                                                        \-                      5                 Moderate
  **Case-control study**                                                                                                                                                                                                                                                                                                                                                           
                            **Selection**                          **Comparability**                     **Exposure**                                                                                                                                                                                                                                                              
  **Study**                 **Is the case definition adequate?**   **Representativeness of the cases**   **Selection of controls**   **Definition of controls**   **Comparability of cases and controls on the basis of design or analysis**   **Ascertainment of exposure**   **Same method of ascertainment for cases and controls**   **Non-response rate**   **Total stars**   **Risk of bias**
  Kawaguchi, T\[[@R19]\]    \*                                     \*                                    \-                          \*                           \-                                                                           \*                              \*                                                        \-                      5                 Moderate
  Bosco, J. L\[[@R21]\]     \*                                     \*                                    \*                          \*                           \*                                                                           \*                              \*                                                        \-                      7                 Low
  Monami, M\[[@R22]\]       \*                                     \*                                    \-                          \*                           \*                                                                           \*                              \*                                                        \-                      6                 Moderate
  Chang, C. H.\[[@R25]\]    \*                                     \*                                    \-                          \*                           \*                                                                           \*                              \*                                                        \-                      6                 Moderate
  Origasa H,\[[@R33]\]      \*                                     \-                                    \-                          \*                           \*                                                                           \*                              \*                                                        \-                      5                 Moderate
  Simo, R.\[[@R34]\]        \*                                     \-                                    \*                          \*                           \*                                                                           \*                              \*                                                        \-                      6                 Moderate
  Dabrowski, M.\[[@R38]\]   \*                                     \-                                    \-                          \*                           \*\*                                                                         \*                              \*                                                        \-                      6                 Moderate

AGI and the risk of any cancer {#s2_3}
------------------------------

Of the 25 studies (21 observational and 4 RCTs) that reported on the association between AGI use and cancer risk, 4 demonstrated a decreased risk of cancer with AGI use \[[@R15], [@R28], [@R31], [@R36]\], 1 showed an increased risk \[[@R25]\], and 20 reported no significant relationship \[[@R16]--[@R24], [@R26], [@R27], [@R29], [@R30], [@R32]--[@R35], [@R37]--[@R39]\]. A meta-analysis of the observational studies demonstrated that AGI use (as compared with nonuse) was associated with a statistically significant 14% reduction in cancer incidence (*n* = 21 studies; odds ratio \[OR\] = 0.86, 95% CI 0.78-0.96) (Figure [2](#F2){ref-type="fig"}). There was considerable heterogeneity between studies (Cochran Q test *P* \< 0.01; *I*^2^ = 82.4%). Of the study characteristics assessed in meta-regression, the quality of study and adjustment for potential confounders were statistically significant (*P* \< 0.01) (Table [3](#T3){ref-type="table"}). Meta-regression analysis did not show any significant effect size modification by other specific study characteristics considered, such as study design, setting, location, or duration of DM.

![Study flow diagram in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations](oncotarget-08-81027-g001){#F1}

![Summary of OR of observational studies assessing the risk of cancer with AGI use](oncotarget-08-81027-g002){#F2}

###### Subgroup analysis

  Subgroups                            No. of studies   OR     95 % CI     I^2^    Meta-Regression *P*-Value
  ------------------------------------ ---------------- ------ ----------- ------- ---------------------------
  Study design                                                                     0.116
  Cohort                               14               0.81   0.70-0.94   84.6%   
  C-C                                  7                1.10   1.05-1.15   0%      
  **Study location**                                                               0.409
  Western                              5                0.99   0.97-1.00   0%      
  Asian                                16               0.83   0.70-0.98   86.5%   
  **Study setting**                                                                0.629
  Hospital based                       6                0.91   0.72-1.16   0%      
  Population based                     15               0.86   0.77-0.95   87.3%   
  **Quality of study**                                                             0.000
  Low risk of bias                     13               0.73   0.65-0.83   25.3%   
  Moderate risk of bias                8                1.03   0.95-1.11   70.0%   
  **Multivariate adjusted analysis**                                               0.007
  Yes                                  14               0.76   0.63-0.92   84.5%   
  No                                   7                1.08   1.04-1.13   0%      
  **Duration of DM**                                                               0.577
  New-onset                            10               0.80   0.66-0.97   91.7%   
  Less than 10 years                   3                0.84   0.63-1.11   0%      
  Moe than 10 years                    1                1.25   0.56-2.75   \-      

In subgroup analyses, the proactive association was detected in cohort studies, population-based studies, studies adjusting for covariates, Asian population, new-onset diabetic patients, and studies with low risk of bias. The subgroup analyses suggested an increased risk in case-control studies and in studies not adjusted for potential confounders. Sufficient data were not available to analyze the impact of AGI dose and duration.

Meta-analysis of RCTs revealed no significant association of AGI with cancer risk (*n* = 4 studies; OR = 0.83, 95% CI 0.20-3.46, *I*^2^ = 0%) ([Figure S2](#SD1){ref-type="supplementary-material"}).

AGI and cancer risk for individual tumor types {#s2_4}
----------------------------------------------

Seventeen studies (16 observational studies and 1 RCT) reported the risk of cancer for individual tumor types in AGI users compared with non-users. The relationship between AGI use and risk for each tumor type is shown in Figure [3](#F3){ref-type="fig"}. As there were 4 Taiwanese studies on colorectal cancer from the same cohort \[[@R15], [@R25], [@R32], [@R36]\], the study with the largest cohort size was included \[[@R15]\]. Two studies presented data on colon and rectum cancer separately, which were pooled to derive a summary estimate for the study \[[@R16], [@R32]\]. The association between AGI use and decreased risk of cancer was most prominent in patients with lung cancer (*n* = 2 studies; OR = 0.70, 95% CI 0.52-0.93, *I*^2^ = 0%). There was a slight trend toward lower risk of colorectal, liver, gastric, and breast cancer with AGI use (OR = 0.79, 95% CI 0.54-1.15, *I*^2^ = 96%; OR = 0.89, 95.5 % CI 0.75-1.05, *I*^2^ = 89.7%; OR = 0.69, 95% CI 0.36-1.31, *I*^2^ = 55.6%; OR = 0.74, 95% CI 0.37-1.51, *I*^2^ = 66.2%, respectively); however, these associations were not statistically significant. No significant associations were identified for pancreatic, esophageal, and urothelial cancer. A meta-analysis of studies of gastrointestinal cancer (Figure [4](#F4){ref-type="fig"}) showed a significant association between AGI use and reduced cancer risk (OR = 0.83, 95% CI 0.71-0.97, *I*^2^ = 89.9%).

![AGI and the cancer risk for individual tumor types](oncotarget-08-81027-g003){#F3}

![AGI and the risk for gastrointestinal cancer](oncotarget-08-81027-g004){#F4}

Publication bias {#s2_5}
----------------

There was no evidence of significant publication bias, both quantitatively (*P* = 1.0 for Begg\'s test, *P* = 0.116 for Egger\'s test) and qualitatively, on visual inspection of the funnel plot ([Figure S3](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

This study showed an overall reducing effect of AGI on cancer risk, which was inconsistent with the previous meta-analysis \[[@R7]\]. The previous meta-analysis noted a significantly increased risk with AGI only in the case-control studies, but not in the cohort studies or RCTs \[[@R7]\]. In addition, the meta-analysis included only two cohort studies and omitted important recent studies on the influence of AGI on cancer risk. Furthermore, subgroup analyses were not performed. In subgroup analyses of our present analysis, the association between AGI and cancer risk was more prominent in population-based studies, studies with low risk of bias, and studies adjusted for covariates, indicating that more prospective, well-designed studies are warranted to confirm the results.

Various explanations have been provided for the association between diabetes and cancer. Metformin has been shown to possess anti-cancer property both *in vivo* and *in vitro* \[[@R9]\]. It has been proposed that metformin exerts its anti-cancer properties through direct effects on cancer cells, particularly through inhibition of the AMPK/mTOR pathway, and indirect effects by decreasing glucose, insulin, insulin-like growth factor 1 (IGF-1) levels, and other inflammatory factors \[[@R9]\].

Metformin is the only first-line oral ADM recommended by international guidelines for the treatment of type 2 diabetes \[[@R40]\]. AGI is another inexpensive and well-tolerated drug that has been widely used to treat DM for more than 20 years \[[@R41]\]. AGIs have shown better glucose-lowering effect in Asian populations than in Western populations \[[@R42]\], and acarbose has shown to exhibit an efficacy similar to that of metformin in China \[[@R43]\]. Yang et al showed that acarbose diminished insulin and glucagon concentrations while increasing GLP-1 concentration in Chinese type 2 diabetic patients \[[@R43]\]. A previous study also revealed that acarbose treatment reduced postprandial hyperinsulinemia \[[@R44]\].

Besides hypoglycemic effect, acarbose has been shown to possess anti-inflammatory and immunomodulatory effects in animal and human studies involving both Western and Asian type 2 DM patients \[[@R45]--[@R47]\]. Three mechanisms can be implicated for these actions. First, acarbose may regulate gut hormones. Previous studies demonstrated that acarbose use increased GLP-1 in the serum \[[@R43], [@R48]--[@R51]\]. Second, acarbose may interact with gut microbiota. A recent study found that acarbose increased the content of gut *Bifidobacterium longum* in type 2 DM patients \[[@R47]\], which could help to reduce intestinal inflammation \[[@R52]\]. Third, the unabsorbed acarbose may have an effect on the intestinal immune system by suppressing pro-inflammatory cytokine expression in the gut \[[@R53]\].

Owing to the known effects of AGI on the gut, it can be hypothesized that AGI may modify the risk of gastrointestinal cancer. A study of transformed cells suggested that acarbose exerts antineoplastic effect by increasing butyrate production \[[@R54]\], which has protective effect against colonic cancer \[[@R55]\]. Previous studies suggested that fecal butyrate, which is a short-chain fatty acid, is a key colonocyte nutrient and an important survival factor for colonic epithelial cells \[[@R56]\]. Acarbose has been found to reduce the colonic transit time and thus change the fecal concentration of bile acids, which may have protective effect against colorectal cancer \[[@R57], [@R58]\]. In addition, acarbose use has been found to be associated with increased production of GLP-1 \[[@R43], [@R48]--[@R51]\]. Previous studies indicated GLP-1 as a potent inducer of cAMP and an inhibitor of breast cancer cell proliferation \[[@R59]\]. A study using CT26 tumor-bearing BALB/c mice showed that GLP-1 receptor agonist treatment increased tumor apoptosis \[[@R60]\]. In the APC gene knockout animal model, which develops multiple intestinal adenomas, acarbose had a regressive effect on the size of gastrointestinal adenomas but did not significantly decrease the number of colonic neoplasms \[[@R61]\]. Most recently, a cohort study of DM patients in Taiwan showed that acarbose use reduced the risk of incident colorectal cancer in patients with diabetes in a dose-dependent manner \[[@R15]\]. Our analysis showed an overall reducing effect of AGI on gastrointestinal cancer risk. However, only a slight trend toward lower risk was observed in colorectal cancer, liver cancer, and gastric cancer, which was not statistically significant. It is difficult to identify the effects of AGI on gastrointestinal cancer based on retrospective studies due to confounding by indication and reverse causality. More prospective observational studies, which account for these sources of heterogeneity, would be required to truly assess the impact of AGI on the risk of gastrointestinal cancer.

Our analysis showed that AGI use was associated with a slightly decreased risk in patients with lung cancer (*n* = 2 studies; OR, 0.86; 95% CI, 0.76-0.97). The associations observed between ADMs and lung cancer were not consistent \[[@R62]--[@R64]\]. The precise mechanism of the observed cancer risk reduction is not clear. The results of our analysis should be interpreted with caution as only two studies were included in the analysis.

The strengths of our study include the comprehensive and simultaneous assessment of the effects of AGI on the risk modification of cancer, and findings from multiple subgroup analyses to ensure stability of the association and identify factors responsible for heterogeneity.

There were also several limitations to our meta-analysis. First, the cancer-modifying association between AGI and cancer risk were based on data from observational studies, was apparent based on the RCT cases. In observational studies, random allocation of the intervention is not done, which is necessary to test the exposure-outcome hypothesis optimally. As a result, the chemopreventive effect of AGI seen in observational studies may be an overestimate of its true effect. However, we should acknowledge that the average follow-up time in observational studies is much longer than that in RCTs, which could explain why current clinical trials of AGI for the management of DM do not demonstrate a significant effect on cancer. Second, all studies were not adjusted for the same confounders. In addition, most patients with DM in these studies were on multiple ADMs simultaneously. As a result, as compared with patients on AGI, patients "not on AGI" (the comparator group) would be more likely to be on metformin. Therefore, it is difficult to interpret whether the risk modification inferred for any one agent is real or confounded by exposures to other ADMs. In the only monotherapy, population-based observational study conducted by Chen et al to compare cancer incidence with metformin and other ADMs in patients with DM, AGI use was not found to be associated with risk of cancer \[[@R35]\]. The true clinical effect of AGI on cancer risk should ideally be studied by comparing patients on AGI therapy for DM with those managed by non-medical/dietary therapy over an extended period of time.

In conclusion, meta-analysis of existing studies suggests a protective association between AGI use and risk of cancer in patients with DM. As there was considerable heterogeneity across studies, future, well-designed, prospective studies are warranted to evaluate this association better.

MATERIALS AND METHODS {#s4}
=====================

This systematic review was conducted following guidance provided by the Cochrane Handbook \[[@R65]\] and is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@R66]\].

Data sources, searches, and study selection {#s4_1}
-------------------------------------------

First, a systematic literature search of MEDLINE (1966 through September 30, 2016), EMBASE (1988 through September 30, 2016), and Web of Science (1993 through September 30, 2016) databases was conducted by two study investigators for all relevant articles on the association between AGI use and risk of cancer in patients with DM. The following keywords and/or corresponding MeSH terms were used: (acarbose OR voglibose OR miglitol OR alpha glucosidase inhibitor OR alpha glucoside hydrolase inhibitor OR α glucosidase inhibitor OR α glycoside hydrolase inhibitor) AND (cancer OR tumor OR neoplasm). The title and abstract of studies identified in the search were reviewed by two authors independently to exclude studies that did not answer the research question of interest. The full text of the remaining articles was examined to determine whether it contained relevant information. Next, bibliographies of the selected articles, as well as review articles on the topic were manually searched for additional articles. Third, manual search of abstracts from major endocrinology and oncology conferences (2007-2016) was performed for additional abstracts on the topic. When information available was not complete, attempts were made to contact the corresponding authors of the studies for additional information.

Studies considered in this meta-analysis were either observational studies or RCTs that met the following inclusion criteria: (1) evaluated and clearly defined exposure to AGI, (2) reported cancer outcomes in patients with DM, and (3) reported relative risks or odds ratio (OR) or provided data for their estimation. Inclusion was not otherwise restricted by study size, language, or publication type. When there were multiple publications from the same population, only data from the most comprehensive report were included. The flow diagram summarizing study identification and selection is shown in Figure [1](#F1){ref-type="fig"}.

Data extraction and quality assessment {#s4_2}
--------------------------------------

Data were independently abstracted onto a standardized form by two reviewers. The following data were collected from each study: study design, time period of study/year of publication, location/setting of the population studied, type of DM, duration of DM, age/sex of patients included, type of tumor, dose and duration of AGI use (if reported), information source of exposure ascertainment and outcome assessment, total number of persons, OR, and 95% CI with and without adjustment for confounding factors. When data on individual tumor types were reported separately, we pooled these to derive a summary estimate for the study. For all analysis, referent group was composed of patients with DM not exposed to AGI. Conflicts in data abstraction were resolved by consensus, referring back to the original article.

Quality assessment for observational studies was performed using the Newcastle Ottawa scale \[[@R67]\]. A score of 7-9 represents low risk of bias, 4-6 represents moderate risk of bias, and 0-3 represents high risk of bias. The quality of RCTs was assessed using a revised form of Cochrane Collaboration\'s tool for assessing risk of bias in randomized trials \[[@R68]\]. This tool focuses on the adequacy of randomization and allocation concealment procedures, blinding, and loss to follow-up. Any discrepancies were addressed by a joint reevaluation of the original article.

Data synthesis and analysis {#s4_3}
---------------------------

The primary analysis focused on assessing the relationship between AGI and risk of cancer in patients with DM. A priori hypotheses to explain potential heterogeneity in the direction and magnitude of effect among different observational studies included type of cancer, location/setting of study (Western population *vs*. Asian population; population based *vs*. hospital based), study design (case-control *vs*. cohort), quality of study (low bias *vs*. moderate bias *vs*. high bias), and whether the study was adjusted for the potential confounding factors. Because of significant differences in the design of observational studies and RCTs, data from these RCTs were analyzed and presented separately.

We used the random-effects model described by DerSimonian and Laird to calculate meta-analytic OR and 95% CI \[[@R69]\]. Adjusted ORs reported in studies were used for analysis to account for confounding variables. We assessed heterogeneity between study-specific estimates with the Cochran Q statistic (*P* \< 0.10) and I^2^ statistic \[[@R69], [@R70]\]. Once heterogeneity was noted, between-study sources of heterogeneity were investigated using subgroup and meta-regression analyses by study characteristics (as described above). All *P* values were two-tailed. For all tests (except for heterogeneity and publication bias), a *P* value of less than 0.05 was considered statistically significant. Subgroup analysis was conducted on all relevant study characteristics regardless of statistical significance. We investigated the presence and the effect of publication bias using a combination of the Begg\'s test \[[@R70]\] and Egger\'s test \[[@R71]\]. Statistical analyses were performed using Stata 12.1 (StataCorp). An overview of the study protocol is provided in S1 Protocol.
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